Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 12 | 2024 | 237 | 4.090 |
Why?
|
| Brachytherapy | 8 | 2024 | 75 | 2.990 |
Why?
|
| Radiosurgery | 4 | 2020 | 111 | 1.920 |
Why?
|
| Genital Neoplasms, Female | 2 | 2024 | 46 | 1.460 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 2515 | 1.040 |
Why?
|
| Neoplasms | 5 | 2022 | 2792 | 1.030 |
Why?
|
| Radiation Injuries | 3 | 2019 | 142 | 0.980 |
Why?
|
| Radiotherapy | 5 | 2020 | 135 | 0.930 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2024 | 70 | 0.900 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 668 | 0.890 |
Why?
|
| Radiation Oncology | 1 | 2022 | 23 | 0.800 |
Why?
|
| Cultural Diversity | 1 | 2022 | 63 | 0.790 |
Why?
|
| Precision Medicine | 1 | 2024 | 319 | 0.710 |
Why?
|
| Radiotherapy Dosage | 3 | 2020 | 183 | 0.700 |
Why?
|
| Pain, Procedural | 1 | 2020 | 8 | 0.700 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 189 | 0.680 |
Why?
|
| Occupational Injuries | 1 | 2020 | 10 | 0.680 |
Why?
|
| Musculoskeletal System | 1 | 2020 | 18 | 0.680 |
Why?
|
| Anesthesia, Local | 1 | 2020 | 47 | 0.670 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2020 | 33 | 0.670 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 58 | 0.660 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 80 | 0.640 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1026 | 0.640 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 72 | 0.640 |
Why?
|
| Analgesics | 1 | 2020 | 127 | 0.640 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 51 | 0.630 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 99 | 0.620 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 234 | 0.610 |
Why?
|
| Hydrocodone | 1 | 2018 | 32 | 0.590 |
Why?
|
| Codeine | 1 | 2018 | 22 | 0.590 |
Why?
|
| Hormones | 1 | 2019 | 186 | 0.580 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1104 | 0.580 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 152 | 0.580 |
Why?
|
| Neoplasm Staging | 8 | 2022 | 1275 | 0.580 |
Why?
|
| Lung Injury | 1 | 2019 | 122 | 0.560 |
Why?
|
| Acetaminophen | 1 | 2018 | 92 | 0.550 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 435 | 0.530 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 343 | 0.530 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 103 | 0.530 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 248 | 0.530 |
Why?
|
| Female | 28 | 2024 | 66885 | 0.500 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2024 | 63 | 0.460 |
Why?
|
| Androgen Antagonists | 1 | 2015 | 120 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 503 | 0.440 |
Why?
|
| Humans | 35 | 2024 | 125392 | 0.440 |
Why?
|
| Databases, Factual | 4 | 2020 | 1186 | 0.440 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 255 | 0.440 |
Why?
|
| United States | 9 | 2022 | 10936 | 0.430 |
Why?
|
| Quality of Life | 2 | 2022 | 1945 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 616 | 0.400 |
Why?
|
| Middle Aged | 13 | 2024 | 26990 | 0.380 |
Why?
|
| Aged | 9 | 2020 | 19896 | 0.370 |
Why?
|
| SEER Program | 3 | 2020 | 202 | 0.370 |
Why?
|
| Adult | 12 | 2024 | 29692 | 0.360 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 1216 | 0.320 |
Why?
|
| Patient Positioning | 1 | 2010 | 54 | 0.320 |
Why?
|
| Safety-net Providers | 2 | 2022 | 52 | 0.310 |
Why?
|
| Skin | 2 | 2019 | 519 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 341 | 0.300 |
Why?
|
| Family Planning Services | 2 | 2024 | 37 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2020 | 16389 | 0.280 |
Why?
|
| Propensity Score | 2 | 2018 | 222 | 0.270 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1549 | 0.250 |
Why?
|
| Survival Rate | 3 | 2020 | 2062 | 0.250 |
Why?
|
| Young Adult | 5 | 2019 | 9069 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 872 | 0.240 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 166 | 0.230 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6607 | 0.220 |
Why?
|
| Physicians, Women | 1 | 2024 | 47 | 0.220 |
Why?
|
| Lymph Nodes | 1 | 2005 | 379 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2017 | 473 | 0.210 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2022 | 11 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1140 | 0.200 |
Why?
|
| Oncologists | 1 | 2022 | 29 | 0.200 |
Why?
|
| Anthracyclines | 1 | 2021 | 36 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 348 | 0.190 |
Why?
|
| Infertility | 1 | 2022 | 78 | 0.190 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 306 | 0.190 |
Why?
|
| Cisplatin | 2 | 2020 | 249 | 0.180 |
Why?
|
| Urban Population | 1 | 2022 | 228 | 0.180 |
Why?
|
| Age Factors | 3 | 2019 | 2827 | 0.180 |
Why?
|
| Promethazine | 1 | 2020 | 5 | 0.180 |
Why?
|
| Hydromorphone | 1 | 2020 | 11 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 249 | 0.170 |
Why?
|
| Lorazepam | 1 | 2020 | 12 | 0.170 |
Why?
|
| Organs at Risk | 1 | 2020 | 24 | 0.170 |
Why?
|
| Antiemetics | 1 | 2020 | 22 | 0.170 |
Why?
|
| Ibuprofen | 1 | 2020 | 40 | 0.170 |
Why?
|
| Rectum | 1 | 2020 | 99 | 0.160 |
Why?
|
| Anti-Anxiety Agents | 1 | 2020 | 74 | 0.160 |
Why?
|
| Emotions | 1 | 2022 | 357 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2018 | 1506 | 0.160 |
Why?
|
| Radiation Pneumonitis | 1 | 2019 | 13 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 139 | 0.160 |
Why?
|
| Esomeprazole | 1 | 2019 | 32 | 0.160 |
Why?
|
| Mastectomy, Radical | 1 | 2019 | 8 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 897 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2020 | 242 | 0.160 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 6 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2019 | 88 | 0.150 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 14 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 33 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 67 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2107 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2018 | 42 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 109 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 363 | 0.140 |
Why?
|
| Fibrosis | 1 | 2019 | 437 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 267 | 0.140 |
Why?
|
| General Surgery | 1 | 2019 | 206 | 0.140 |
Why?
|
| Medicare | 1 | 2020 | 428 | 0.130 |
Why?
|
| Male | 8 | 2020 | 61663 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 686 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1496 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 339 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3741 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 620 | 0.130 |
Why?
|
| Logistic Models | 2 | 2018 | 1815 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1244 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1659 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2018 | 12412 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 63 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1240 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 85 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1251 | 0.120 |
Why?
|
| Mastectomy, Segmental | 2 | 2015 | 27 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 272 | 0.110 |
Why?
|
| Radiography | 2 | 2022 | 823 | 0.110 |
Why?
|
| Prevalence | 1 | 2020 | 2467 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 595 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 1691 | 0.110 |
Why?
|
| Carcinoma | 1 | 2015 | 287 | 0.100 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 40 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1115 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2022 | 1185 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 1446 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2022 | 6168 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1361 | 0.090 |
Why?
|
| Fertility | 2 | 2024 | 259 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2020 | 4824 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 584 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 3468 | 0.080 |
Why?
|
| Electrons | 1 | 2010 | 24 | 0.080 |
Why?
|
| Pain | 1 | 2013 | 451 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 4648 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3589 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 409 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 10331 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 3004 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 604 | 0.060 |
Why?
|
| Child | 3 | 2022 | 24436 | 0.060 |
Why?
|
| Adolescent | 2 | 2019 | 19373 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2005 | 334 | 0.060 |
Why?
|
| Infant | 1 | 2019 | 12518 | 0.060 |
Why?
|
| Sexism | 1 | 2024 | 38 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2005 | 143 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2019 | 14030 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 1568 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 78 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2024 | 142 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 217 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 44 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3583 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 641 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 192 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 117 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 2 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 23 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 677 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 100 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 114 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 293 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 333 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 460 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6345 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 144 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1630 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1058 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 590 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 308 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2013 | 5 | 0.030 |
Why?
|
| Infusions, Spinal | 1 | 2013 | 2 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 880 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 121 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1756 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1711 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1260 | 0.020 |
Why?
|
| Reference Standards | 1 | 2013 | 236 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1442 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1527 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 178 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4406 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7223 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4396 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2917 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5185 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 17637 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 34241 | 0.010 |
Why?
|